The implication of monitoring tumour markers: a personalised medicine approach
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Poster
- By: GRECH, Louise (University of Malta, Pharmacy, Attard, Malta)
- Co-author(s): Charyl Fava: Pharmacy, University of Malta, Msida, Malta
Louise Grech: Pharmacy, University of Malta, Msida, Malta;Pharmacy, Mater Dei Hospital, Msida, Malta
Rachel Micallef: Oncology, Sir Anthony Mamo Oncology Centre, Msida, Malta
Stefan Laspina: Haematology and Oncology, Mater Dei Hospital, Msida, Malta
Christopher Barbara: Pathology, Mater Dei Hospital, Msida, Malta
Lilian M. Azzopardi: Pharmacy, University of Malta, Msida, Malta
The availability of tumour markers in managing oncology patients contributes to developing personalised pharmacotherapy.
To develop and implement a pharmaceutical personalised approach based on harmaceutical care plan (PCP) incorporating tumour markers for patients suffering from ovarian, pancreatic or prostate cancer.
Drug.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.